Status:
COMPLETED
Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule
Lead Sponsor:
Gustavo Viani Arruda
Conditions:
Prostate Cancer
Eligibility:
MALE
18-75 years
Phase:
PHASE3
Brief Summary
There is no randomized controlled trial (RCT) comparing Conformal Radiotherapy (3DCRT) versus the Intensity Modulated Radiotherapy (IMRT) in terms of toxicity and disease control. Data from retrospect...
Eligibility Criteria
Inclusion
- Patients with diagnosis of prostate cancer
- With age between 18-75 years classified in low
- Intermediate and high-risk group according to their Gleason score
- T stage and initial PSA (iPSA).
- Low risk group included patients with Gleason score \<7 / stage T1-T2a, and iPSA \<10 ng/mL.
- Intermediate risk included Gleason score \< 7, or Stage T1-T2b, or iPSA level of 10-20 ng/mL
- High-risk patients with Gleason score \>7, or Stage \> T2b, or iPSA \>20 ng/mL.
- All patients classified as high risk was submitted to the bone scans.
Exclusion
- Patients with metastases
- Prior history of prostatectomy
- Pelvic radiotherapy treatment
- Chemotherapy treatment were excluded of this trial.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT02257827
Start Date
January 1 2009
End Date
January 1 2013
Last Update
October 6 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine of Marilia
Marília, São Paulo, Brazil